JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Rapport Therapeutics, Inc. (RAPP) Receives a Buy From TD Cowen
Rapport Therapeutics' Promising Trial Results and Leadership Change
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate
Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of...
Express News | Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025
Express News | Rapport Therapeutics Inc - Rap-219 Well Tolerated in Mad-2 Trial
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Express News | Rapport Therapeutics Announces New Phase 1 Data, Further Supporting Rap-219's Transformative Potential for CNS Disorders
Rapport Therapeutics (NASDAQ:RAPP) Is In A Strong Position To Grow Its Business
Jefferies Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $35
Rapport Therapeutics, Inc. (RAPP) Receives a Buy From Jefferies
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn
Rapport Therapeutics Reports Correlation Between Seizure Biomarker, Clinical Seizures
Express News | Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in Rns Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Promising Developments and Strategic Focus Bolster Buy Rating for Rapport Therapeutics